[Comment] Beyond monotherapy: chemotherapy-free strategies in first-line advanced non-small-cell lung cancer
Summary
For more than a decade, immune checkpoint inhibitors (ICIs) have played a central part in the treatment landscape of advanced non-small-cell lung cancer (NSCLC).1 These therapies have improved survival both as monotherapy and in combination with chemotherapy and altered expectations for patients with metastatic disease. Yet their benefit is not universal. A substantial proportion of patients (∼18%) derive little or…
For more than a decade, immune checkpoint inhibitors (ICIs) have played a central part in the treatment landscape of advanced non-small-cell lung cancer (NSCLC).1 These therapies have improved survival both as monotherapy and in combination with chemotherapy and altered expectations for patients with metastatic disease. Yet their benefit is not universal. A substantial proportion of patients (∼18%) derive little or no clinical improvement, and some experience rapid deterioration with primary resistance.